Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.
Published . Updated .
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
Directly affected
- No company is named in this report.
Indirectly affected
- No related companies are mapped for this report yet.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
Source: MarketWatch
This story
12 out of 100
“Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.” scores 12 out of 100. The score uses 1 sources.